Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Cervical cancer vaccine candidate induced a higher immune response in young girls
January 26th, 2006
Cervarix, GlaxoSmithKline's candidate cervical cancer vaccine, formulated with the adjuvant AS04, induced antibody levels against the two most common cancer-causing HPV types (HPV 16/18) at least two-fold higher in 10-14 year-old adolescent girls, than in women 15-25 years old, a new study shows. The candidate vaccine for cervical cancer was also shown to induce antibodies in 100% of volunteers in both age groups one month after completion of the course of vaccination. The vaccine in the present study was well tolerated and adverse event rates were similar in each age group. No vaccine-related serious adverse events were reported. Recent positive...
Source: Women's Health Weekly (2006-01-26)
|
